Chris I Wong

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Placebo Controlled

Cerebral Blood Flow

Quality Improvement

Palliative Care

Top Venues

Pediatric blood & cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Chris I Wong, Maya Ilowite, Adam Paul Yan, Riley M Mahan, Marie D Desrochers, Margaret Conway, Amy L Billett
Reducing ambulatory central line-associated bloodstream infections: A family-centered approach. Pediatric blood & cancer (2024)
Jeffrey G Edwards, Adam Paul Yan, Ramy Yim, Mo Oni, Matthew M Heeney, Dave Johnson, Chris I Wong, Maya Ilowite, Natasha M Archer
Sustained increase in annual transcranial Doppler screening rates in children with sickle cell disease: A quality improvement project. Pediatric blood & cancer 71 (8) (2024)
Jeffrey G Edwards, Adam Paul Yan, Ramy Yim, Mo Oni, Matthew M Heeney, Dave Johnson, Chris I Wong, Maya Ilowite, Natasha M Archer
Sustained increase in annual transcranial Doppler screening rates in children with sickle cell disease: A quality improvement project. Pediatric blood & cancer (2024)
Chris I Wong, Maya Ilowite, Adam Paul Yan, Riley M Mahan, Marie D Desrochers, Margaret Conway, Amy L Billett
Reducing ambulatory central line-associated bloodstream infections: A family-centered approach. Pediatric blood & cancer 71 (8) (2024)
Chris I Wong, Maya Ilowite, Adam Paul Yan, Riley M Mahan, Marie D Desrochers, Margaret Conway, Amy L Billett
Reducing ambulatory central line-associated bloodstream infections: A family-centered approach. Pediatric blood & cancer 71 (8) (2024)
Jeffrey G Edwards, Adam Paul Yan, Ramy Yim, Mo Oni, Matthew M Heeney, Dave Johnson, Chris I Wong, Maya Ilowite, Natasha M Archer
Sustained increase in annual transcranial Doppler screening rates in children with sickle cell disease: A quality improvement project. Pediatric blood & cancer 71 (8) (2024)
Chris I Wong, Daniel J Benedetti, Pei-Chi Kao, Clement Ma, Karen J Marcus, Elizabeth A Mullen
Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors. Pediatric blood & cancer (2023)